Rafael Holdings, Inc.
No SEC Form 4 filings for $RFL in the last 30 days.
See all $RFL insider activity →Rafael Holdings Inc Class B (RFL) shares dropped 25% premarket after its Phase 3 trial for Trappsol Cyclo in Niemann-Pick Disease Type C missed the primary endpoint. The drug showed a 64% slowing of disease progression but lacked statistical significance (p=0.19). A subgroup analysis found significant results (p=0.046). The company plans to submit a New Drug Application by Q4 2026.
Rafael Holdings, Inc. (RFL) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Rafael Holdings Announces Topline Results from the Pivotal Phase 3 TransportNPC ™ Study of Trappsol ® Cyclo ™ in Niemann-Pick Disease Type C (NPC) Trappsol ® Cyclo™ did not achieve statistical significance but demonstrated a directionally favorable treatment effect v
Rafael Holdings (RFL) reported Phase 3 results for Trappsol® Cyclo™ in Niemann-Pick Disease Type C (NPC). While the primary endpoint did not achieve statistical significance, a prespecified analysis in patients on background therapy showed a significant benefit. The drug was well-tolerated. The company plans to submit an NDA in Q4 2026.
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning RFL (Rafael Holdings, Inc.). Coverage has skewed bearish: 1 bullish, 1 neutral, and 3 bearish.
Recent RFL coverage spans financial news, market movers and earnings.
The missed primary endpoint is expected to drive immediate selling pressure on RFL.
Positive prespecified subgroup data may boost investor confidence and drive the stock higher.
Trial data may lift RFL on the back of a positive subgroup result and an on‑track NDA filing, but the primary endpoint missed significance, limiting upside.
Clinical execution milestone plus updated regulatory timeline, alongside cash burn and higher R&D from Cyclo consolidation.
Rafael Holdings reports increased R&D spending and wider losses, but maintains liquidity for at least 12 months. The focus on advancing its lead drug candidate may positively influence future valuations, though current financials are weak.
AlphAI scores every news story that mentions RFL with an AI model for sentiment and relevance, and aggregates insider trades from Rafael Holdings, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Rafael Holdings Inc Class B (RFL) shares dropped 25% premarket after its Phase 3 trial for Trappsol Cyclo in Niemann-Pick Disease Type C missed the primary endpoint. The drug showed a 64% slowing of disease progression but lacked statistical significance (p=0.19). A subgroup analysis found significant results (p=0.046). The company plans to submit a New Drug Application by Q4 2026.
2 min readRafael Holdings, Inc. (RFL) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Rafael Holdings Announces Topline Results from the Pivotal Phase 3 TransportNPC ™ Study of Trappsol ® Cyclo ™ in Niemann-Pick Disease Type C (NPC) Trappsol ® Cyclo™ did not achieve statistical significance but demonstrated a directionally favorable treatment effect v
2 min readRafael Holdings (RFL) reported Phase 3 results for Trappsol® Cyclo™ in Niemann-Pick Disease Type C (NPC). While the primary endpoint did not achieve statistical significance, a prespecified analysis in patients on background therapy showed a significant benefit. The drug was well-tolerated. The company plans to submit an NDA in Q4 2026.
2 min readRafael Holdings, Inc. (RFL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ea029432001ex99-1.htm PRESS RELEASE, DATED JUNE 11, 2026, REPORTING THE RESULTS OF OPERATIONS FOR THE FISCAL QUARTER ENDED APRIL 30, 2026 Exhibit 99.1 Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results NEWARK, NJ – June 11, 2026 (GLOBE NEWSWIRE) - Rafae
6 min readRafael Holdings (NYSE: RFL) reported a wider net loss of $16.2 million for the six months ended January 31, 2026, compared to $13.6 million in the prior year, primarily due to a significant increase in research and development expenses, which rose to $12.0 million from $2.3 million. The company's revenue increased to $451 thousand, driven by rental income and new product sales. With a cash balance of $37.8 million, Rafael Holdings anticipates having sufficient liquidity for at least the next 12 months as it continues to focus on advancing its lead drug candidate, Trappsol® Cyclo™, through a pivotal Phase 3 clinical trial.
3 min readRafael Holdings, Inc. (NYSE:RFL) held its annual meeting where shareholders elected directors, ratified CohnReznick LLP as their accounting firm, and approved an amendment to the company's 2021 Equity Incentive Plan. This amendment increases the shares of Class B common stock available for grant by 1,000,000. Additionally, the company recently issued warrants as part of its merger with Cyclo Therapeutics, which are now listed on NYSE American.
4 min readCyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is continuing at the recommendation of the Data Monitoring Committee ( DMC ) following their review of prespecified safety and ...
2 min readNEWARK, N.J., April 29, 2025 ( GLOBE NEWSWIRE ) -- Rafael Holdings, Inc. ( NYSE: RFL. NYSE American: RFL-WT ) today announced a rights offering, including key dates and terms. The planned offering is designed to provide existing stockholders and holders of our public warrants ( "Holders" ) the ...
3 min readCyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025
4 min readCyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of ...
2 min read
